Datasheet is currently unavailable. Try again or CONTACT US
p35 Control Protein
1 References
000-001-C12
100 µg
Liquid (sterile filtered)
WB, SDS-PAGE, Biochemical Assay
Borrelia burgdorferi
E. coli
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
p35 Control Protein - 000-001-C12
bba64, Borrelia burgdorferi p35, control protein
Borrelia burgdorferi
E. coli
Recombinant Protein
Target Details
BB-H32, bba64 - View All BB-H32, bba64 Products
p35 is a fusion protein with an MBP tag and was expressed in E. coli. Analysis by SDS-PAGE resulted in a pattern consistent with purified p35 and was estimated to be greater than 90% pure.
Application Details
SDS-PAGE, WB
Biochemical Assay
- View References
p35 is suitable as a control in immunological assays. Specific conditions for reactivity should be optimized by the end user. Expect a band at 69.5 kDa for p35-MBP, (27.1 kDa for p35 and 42.4 kDa for MBP) in size corresponding to p35 by Western blotting in the appropriate cell lysate or extract. p35 kDa protein has been tested in SDS-PAGE and WB.
Formulation
1 mg/ml by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Dry Ice
Store vial at -20 °C prior to opening. Aliquot contents and freeze at -20 °C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
Expiration date is six (6) months from date of receipt.
The p35 kDa protein of the spirochete Borrelia burgdorferi is being investigated for use as an early diagnostic marker of Lyme Disease. Borrelia may change its antigenic composition in its need for adaptation to stresses imposed by changes in conditions from cycling between its arthropod and mammalian hosts. This group of B. burgdorferi proteins may be induced in the tick midgut during the feeding event. The p35 protein elicits a protective immunity from wild type B. burgdorferi. It has been shown that p35 expression in B. burgdorferi is upregulated in the stationary growth phase, and that a temperature of 34°C but not 24°C influenced the expression. The expression of a majority of the proteins expressed in early Lyme disease is affected pH, being abundantly expressed at pH 7.0 (resembling the tick midgut pH of 6.8 during feeding) but only sparsely at pH 8.0 (a condition closer to that of the unfed tick midgut pH of 7.4). The encoding genes may be coregulated. The 35-kDa antigen has been shown to be a statistically significant marker in IgG immunoblots in a study of patients with early Lyme disease who presented with erythema migrans. Recombinant p35 protein may be useful as a diagnostic reagent, especially in combination with other antigens that have been deemed relevant in serodiagnosis of early Lyme disease. Lyme disease proteins are ideal for researchers interested in immunology, neurology, rheumatology, coinfections, autoimmune, and neurodegenerative diseases.
Bowman KA. et al. (2024). Borrelia-specific antibody profiles and complement deposition in joint fluid distinguish antibiotic-refractory from -responsive Lyme arthritis. iScience.
Applications
Protein Assay
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
